Guardant Health, Inc. (GH)
| Market Cap | 12.32B |
| Revenue (ttm) | 982.02M |
| Net Income (ttm) | -416.28M |
| Shares Out | 131.17M |
| EPS (ttm) | -3.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,924,670 |
| Open | 95.75 |
| Previous Close | 97.97 |
| Day's Range | 92.09 - 96.99 |
| 52-Week Range | 34.88 - 120.74 |
| Beta | 1.65 |
| Analysts | Strong Buy |
| Price Target | 117.80 (+25.45%) |
| Earnings Date | Feb 19, 2026 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc... [Read more]
Financial Performance
In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $117.8, which is an increase of 25.45% from the latest price.
News
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 23, 2026, the Compensation Committee of Guardant'...
Allspring Smid Cap Growth Fund Q4 2025 Top Contributors And Detractors
Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetiz...
Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025. Fo...
Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open
Patient and Public Health Groups Invited to Apply for Up to 100 Shield Colorectal Cancer Blood Tests to Support Community Screening Events and Educational Outreach in March PALO ALTO, Calif., Feb. 12,...
Guardant Health to Participate in Upcoming Investor Conferences
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. B...
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
PALO ALTO, Calif. & ROCHESTER, Minn.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for C...
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2025...
Alger Small Cap Focus Fund Q4 2025 Portfolio Update
Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were ...
Guardant Health: Look For Explosive Revenue Growth Ahead
Guardant Health, Inc. is rated a Buy, driven by explosive growth potential in cancer and multi-disease screening, notably via its Shield blood test. GH's Shield is the first FDA-approved blood test fo...
Alger Small Cap Growth Fund Q4 2025 Portfolio Update
Class A shares of the Alger Small Cap Growth Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were...
Artisan Small Cap Fund Q4 2025 Portfolio Activity
During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investme...
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer
On Thursday, the U.S. Food and Drug Administration (FDA) approved Guardant Health Inc.'s (NASDAQ: GH) Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic c...
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guar...
Alger Mid Cap Focus Fund Q4 2025 Portfolio Update
Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Roblox Corp., Robinhood Markets, Inc., and Nebius Group were among the top detractor...
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the Un...
Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth
Guardant Health is rated a strong buy, driven by its Shield blood-based colorectal cancer screening and a transformative collaboration with Quest Diagnostics. GH's Shield test addresses major barriers...
Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended Decembe...
Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered...
Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 44th Annual J.P. Morgan Healt...
Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and Improve Access to Screening
UPPER NYACK, N.Y.--(BUSINESS WIRE)--Colorectal Cancer Detection Is Primary Goal of Global Healthy Living Foundation and Guardant Health.
Where To Invest In 2026: Top 5 Secular Growth Trends
Every once in a while, a secular trend is so obvious that everyone can see it, and that is the case with AI. Drones are another important secular trend that we believe will benefit many areas of the e...
Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health (Nasdaq: GH), a leading precision oncology company, and Trial Library, an AI technology company enabling oncology clinical trials as a care ...